Media, page-10

false equivalence: B looks like A, A was successful therefore B will be successful.
SRX different product, totally different cancer, very different time.

in fact SRX at launch at least had results from a randomised control trial showing benefit over the standard of care chemo at the time in liver metastasis. SRX then invested heavily in trials after that.

That’s what the NZ foundation guy is basically saying here and he’s right , oncosil device is still experimental but looks interesting enough to develop further , and oncosil needs to do the randomised control comparative trials and prove the device’s effectiveness against current standard of care if they want to become standard of care in locally advanced pancreatic cancer. Obvious really.